How Melanocortin, Glutamate, and Neuropeptide Y Systems Interact to Control Appetite and Weight | Research

The takeaway

The melanocortin system (α-MSH/AgRP), glutamatergic signaling, and neuropeptide Y form an interconnected network controlling appetite and metabolism, offering multiple peptide-based therapeutic targets for obesity.

3 interconnected systems
Melanocortin, NPY, and glutamate pathways converge on hypothalamic circuits to regulate appetite and metabolism

What the researchers found

Melanocortin (α-MSH/AgRP), glutamatergic, and NPY systems form an interconnected appetite control network with extensive cross-talk, supporting multi-target therapeutic approaches for obesity.

Why it matters

Understanding how appetite-regulating peptide systems interact is essential for designing next-generation obesity drugs that target multiple pathways simultaneously.

How the study worked

Narrative review of the interplay between melanocortinergic, glutamatergic, and neuropeptide Y systems in appetite regulation and energy homeostasis.

What this study cannot tell us

Review of primarily preclinical evidence. Human brain peptide circuit dynamics are difficult to measure directly. Translation to therapeutics is complex.

How to read the evidence

Comprehensive review of preclinical and mechanistic evidence. Well-established individual pathways with emerging understanding of their interactions.

When this study was published

Published in 2025.

The bigger picture

This maps the peptide network controlling human appetite, providing a blueprint for rational multi-target drug design beyond current GLP-1-only approaches.

Questions still open

Could targeting NPY and melanocortin pathways simultaneously produce weight loss resistant to regain?
How do GLP-1 drugs interact with the melanocortin/NPY/glutamate network?
Are there individual genetic differences in these pathways that predict obesity drug response?

Common questions

What controls appetite in the brain?

Three key peptide systems interact: melanocortins (tell you to stop eating), neuropeptide Y (makes you hungry), and glutamate (modulates both). Understanding how they work together is key to developing better weight loss drugs.

Why not just target one system?

Single-target drugs often fail because the brain compensates through the other systems. Multi-target approaches that address melanocortin, NPY, and related pathways simultaneously may produce more durable weight loss.

Read the original research

Investigating the role of melanocortinergic, glutamatergic and neuropeptide Y systems on hypophagia caused by gastric inhibitory polypeptide (GIP) in broilers.

Poultry science, 105(2), 106324

View on PubMed ↗Publisher’s paper ↗

Citation

Gharaie, Maryam Lotfi; Zendehdel, Morteza; Zarei, Hamed; Mahdavi, Kimia. (2026). Investigating the role of melanocortinergic, glutamatergic and neuropeptide Y systems on hypophagia caused by gastric inhibitory polypeptide (GIP) in broilers.. Poultry science, 105(2), 106324. https://doi.org/10.1016/j.psj.2025.106324